Copeptin level differentiates takotsubo cardiomyopathy from acute myocardial infarction.

Copeptin level differentiates takotsubo cardiomyopathy from acute myocardial infarction. Biomarkers. 2021 Jan 12;:1-4 Authors: Szarpak L, Gasecka A, Opiełka M, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ Abstract Serum concentration of copeptin has a prognostic value in several clinical conditions, including myocardial infarction, stroke, pneumonia or chronic obstructive pulmonary disease. We attempted to conduct a systematic review and meta-analysis to answer the question whether copeptin can be used as a parameter differentiating between takotsubo cardiomyopathy (TTC) and acute myocardial infarction (AMI). We performed a metaanalysis of four studies including 109 patients with TTC and 120 patients with AMI, which showed lower levels of copeptin in the TTC group, compared with the AMI group (MD = -26.60; 95% CI: -48.55, -4.65; P = 0.02). Whether TTC could be a biomarker to differentiate TTC from AMI, remains to be established. PMID: 33433256 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research